Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03RTS
|
||||
| Former ID |
DAP000737
|
||||
| Drug Name |
Celecoxib
|
||||
| Synonyms |
CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Analgesics
|
||||
| Company |
Pfizer
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H14F3N3O2S
|
||||
| InChI |
InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
|
||||
| InChIKey |
RZEKVGVHFLEQIL-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 169590-42-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9791, 535138, 828874, 841958, 5364750, 7847633, 7886547, 7978890, 8150033, 8151729, 11336068, 11361307, 11363326, 11364763, 11365888, 11367325, 11368450, 11369887, 11372927, 11373130, 11373862, 11375487, 11376612, 11378052, 11445401, 11462279, 11485248, 11489392, 11491811, 11491997, 11494246, 11528618, 12015009, 14755918, 17389545, 26612517, 26680503, 26697316, 26747363, 26747364, 29221820, 46392808, 46505596, 46512162, 47365253, 47589055, 47959816, 48110506, 48413391, 48415737
|
||||
| ChEBI ID |
ChEBI:41423
|
||||
| SuperDrug ATC ID |
L01XX33; M01AH01
|
||||
| SuperDrug CAS ID |
cas=169590425
|
||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin G/H synthase 2 | Target Info | Inhibitor | [536549], [549843], [549974] | |
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| NF-kappa B signaling pathway | |||||
| VEGF signaling pathway | |||||
| TNF signaling pathway | |||||
| Retrograde endocannabinoid signaling | |||||
| Serotonergic synapse | |||||
| Ovarian steroidogenesis | |||||
| Oxytocin signaling pathway | |||||
| Regulation of lipolysis in adipocytes | |||||
| Leishmaniasis | |||||
| Pathways in cancer | |||||
| Chemical carcinogenesis | |||||
| MicroRNAs in cancer | |||||
| Small cell lung cancer | |||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| References | |||||
| Ref 536772 | New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. | ||||
| Ref 539915 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2892). | ||||
| Ref 536549 | Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. | ||||
| Ref 549843 | Synflorix, GlaxoSmithKline's pneumococcal vaccine, receives European authorisation. GlaxoSmithKline. March 31 2009. | ||||
| Ref 549974 | Pfizer. Product Development Pipeline. March 31 2009. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.